Add this result to my export selection Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 July 2017 Recommendation ID TA455/1 Question Trials that evaluate utility values (using generic preference-based measures) in children and young Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Degarelix for treating advanced hormone-dependent prostate cancer (TA404/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 August 2016 Recommendation ID TA404/1 Question Further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 January 2016 Recommendation ID TA375/1 Question NICE agreed that further research would be of value to investigate factors which can predict the likelihood Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Ustekinumab for treating active psoriatic arthritis (TA340/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 June 2015 Recommendation ID TA340/1 Question NICE considered that there is an important need for head-to-head comparisons between biological treatments Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 February 2015 Recommendation ID TA333/1 Question NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Sofosbuvir for treating chronic hepatitis C (TA330/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 February 2015 Recommendation ID TA330/1 Question NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 September 2014 Recommendation ID TA322/1 Question NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 August 2014 Recommendation ID TA320/1 Question NICE recommends further research to better inform future cost-effectiveness models of relapsing-remitting Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319/2) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 July 2014 Recommendation ID TA319/2 Question Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316/2) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 July 2014 Recommendation ID TA316/2 Question NICE considered that if enzalutamide is used in routine clinical practice for treating hormone relapsed Type: Evidence Uncertainties (Remove filter)